T-helper cell-response to MHC class II-binding peptides of the renal cell carcinoma-associated antigen RAGE-1. (Q53885791)

22 May 2018

title

T-helper cell-response to MHC class II-binding peptides of the renal cell carcinoma-associated antigen RAGE-1. (English)

1 reference

22 May 2018

author name string

Stassar MJ

1

1 reference

22 May 2018

Raddrizzani L

2

1 reference

22 May 2018

Hammer J

3

1 reference

22 May 2018

Zöller M

4

1 reference

22 May 2018

publication date

1 August 2001

1 reference

22 May 2018

published in

Immunobiology

1 reference

22 May 2018

volume

203

1 reference

22 May 2018

issue

5

1 reference

22 May 2018

page(s)

743-755

1 reference

22 May 2018

Present achievements in the medical treatment of metastatic renal cell carcinoma.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Spontaneous remission of renal cell carcinoma: a case report and immunological correlates

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Human neoplasms elicit multiple specific immune responses in the autologous host

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell response in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Human melanoma therapy in the SCID mouse: in vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Dendritic cells differentiated from human monocytes through a combination of IL-4, GM-CSF and IFN-gamma exhibit phenotype and function of blood dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

"Panning" for lymphocytes: a method for cell selection

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Immunology and immunotherapy of human cancer: present concepts and clinical developments

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Origin, maturation and antigen presenting function of dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Dendritic cells in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

1 reference

7 January 2021

Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

The role of CD4+ T cell responses in antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2801%2980003-6

7 January 2021

10.1016/S0171-2985(01)80003-6

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018